Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sinupret oral drops real-world study in pediatric acute sinusitis
ChiCTR2400086951Phase 4Not yet recruiting
- Sponsor
- Zhengzhou Children's Hospital
- Start
- Jul 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Sambucus nigra flower in acute rhinosinusitis (ARS), sponsored by Zhengzhou Children's Hospital. Primary endpoint: Proportion of patients with complete or near-complete disappearance of major symptoms on day 7. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
Sambucus nigra flower
03
Conditions
acute rhinosinusitis (ARS)
Beyond the preview
Go deeper on ChiCTR2400086951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086951.